To:USPTO RECEIVED **CENTRAL FAX CENTER** MAY 2 5 2007

Appl. No.: 10/804,938

Atty. Dkt. No.: 10031165-1

In the Claims:

- 1. (Currently amended) A method of preparing a cRNA sample substantially free of contaminants, comprising the following steps:
 - (a) preparing a cRNA sample;
 - (b) adding an organic solvent to said preparation of (a);
- (c) contacting a[[n]] cRNA isolation column with the organic preparation of step (b), wherein said cRNA isolation column comprises a membrane selected from the group consisting of polysulfone treated with hydroxypropylcellulose, PVDF (polyvinylidene fluoride), nylon, nitrocellulose, polysulfone, polysulfone and polyvinylpyrrolidone, PVP (polyvinylpyrrolidone), and composites thereof;
 - (d) adding to a preparation of step (c) one or more DNase enzymes;
- (e) adding to a preparation of step (d) a wash buffer comprising a chaotropic salt; and
 - (f) eluting said cRNA in a purified form from said column of step (c).

Claim 2 (cancelled).

- 3. (Currently amended) The method of claim [[2]]1, wherein said membrane is a [[MMM]] polysulfone and polyvinylpyrrolidone membrane.
- 4. (Currently amended) The method of claim 3, wherein said [[MMM]] polysulfone and polyvinylpyrrolidone membrane is an asymmetric membrane comprised of polysulfone and PVP.
- 5. (Currently amended) The method of claim 3, wherein said [[MMM]] polysulfone and polyvinylpyrrolidone membrane has a pore size ranging from about 30 to about 40 µm on an upper side, and wherein said [[MMM]] polysulfone and polyvinylpyrrolidone membrane has a pore size ranging from about 0.4 µm to about 0.6 µm on a lower side.

Appl. No.: 10/804,938 Atty. Dkt. No.: 10031165-1

- 6. (Original) The method of claim 5, wherein said membrane has a pore size of about $0.4 \mu m$ on said lower side.
- 7. (Original) The method of claim 1, wherein said cRNA is labeled.
- 8. (Original) The method of claim 7, wherein said label is either radioactive or fluorescent.
- 9. (Original) The method of claim 8, wherein said fluorescent label is a cyanine dye.
- 10. (Original) The method of claim 1, wherein said purified cRNA is from about 55% to about 65% pure.
- 11. (Original) The method of claim 1, wherein said purified cRNA is from about 65% to about 75% pure.
- 12. (Original) The method of claim 1, wherein said purified cRNA is from about 75% to about 85% pure.
- 13. (Original) The method of claim 1, wherein said purified cRNA is from about 85% to about 95% or greater pure.
- 14. (Original) The method of claim 1, wherein said organic solvent is ethanol.
- 15. (Original) The method of claim 1, wherein said isolation column is either a SiCw column or an RNA isolation column.
- 16. (Withdrawn) A kit for isolating cRNA in a form essentially free from contamination, comprising the following: a cRNA isolation column, wherein said column comprises an asymmetric membrane; reagents for (a); and instructions for implementing the isolation of cRNA.
- 17. (Withdrawn) The kit of claim 16, wherein said cRNA isolation column membrane

Appl. No.: 10/804,938 Atty, Dkt. No.: 10031165-1

is selected from the group consisting of BTS, PVDF, nylon, nitrocellulose, polysulfone, MMM, PVP, and composites thereof.

- 18. (Withdrawn) The kit of claim 17, wherein said cRNA isolation column membrane is MMM.
- 19. (Withdrawn) The kit of claim 16, wherein said reagents include at least one organic solvent, nuclease free water, RLT buffer, and RPE buffer.
- 20. (Previously presented) The method of claim 1, wherein said one or more DNase enzymes is selected from the group consisting of DNase 1, DNase II, and a combination thereof.
- 21. (Previously presented) The method of claim 1, wherein said chaotropic salt is selected from the group consisting of guanidine isothiocyanate, ammonium isothiocyanate, guanidine hydrochloride, and a combination thereof.